<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01415518</url>
  </required_header>
  <id_info>
    <org_study_id>D589BL00022</org_study_id>
    <nct_id>NCT01415518</nct_id>
  </id_info>
  <brief_title>Efficacy and Tolerability Study in Severe Chronic Obstructive Pulmonary Disease (COPD) Patients</brief_title>
  <acronym>SECURE2</acronym>
  <official_title>Efficacy and Tolerability Study of Symbicort Turbuhaler(160/4.5µg/Inhalation,2inhalations Twice Daily) Added to Atrovent (20µg/Inhalation, 2 Inhalations 4 Times Daily)+Theophylline SR(0.1g/Tablet,1 Tablet p.o. Twice Daily) Compared With Atrovent+Theophylline SR in Severe COPD Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      Efficacy and tolerability study in severe chronic obstructive pulmonary disease (COPD)
      patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Efficacy and tolerability study of Symbicort Turbuhaler (160/4.5µg/inhalation,2inhalations
      twice daily) added to Atrovent (20µg/inhalation, 2 inhalations 4 times daily) + theophylline
      SR(0.1g/tablet, 1 tablet p.o. twice daily) compared with Atrovent + theophylline SR in severe
      COPD patients.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2011</start_date>
  <completion_date type="Actual">December 2012</completion_date>
  <primary_completion_date type="Actual">December 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pre-dose FEV1</measure>
    <time_frame>Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug</time_frame>
    <description>Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Post-dose FEV1 at 5 Minutes</measure>
    <time_frame>Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug</time_frame>
    <description>Ratio of post-dose FEV1 at 5 minutes to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FEV1 at 60 Minutes</measure>
    <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose FEV1 at 60 minutes to baseline value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose FVC</measure>
    <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of pre-dose FVC (Forced Vital Capacity) to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FVC at 5 Minutes</measure>
    <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose FVC at 5 minutes to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose FVC at 60 Minutes</measure>
    <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose FVC at 60 minutes to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose IC</measure>
    <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of pre-dose IC (Inspiratory Capacity) to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose IC at 60 Minutes</measure>
    <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
    <description>Ratio of post-dose IC at 60 minutes to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose PEF in Last Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment</time_frame>
    <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose PEF in First Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured before inhalation of study drug in the first week of treatment</time_frame>
    <description>Change in pre-dose morning PEF from run-in period to first week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pre-dose PEF in Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period (12 weeks)</time_frame>
    <description>Change in pre-dose morning PEF from run-in period to whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose PEF in Last Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment</time_frame>
    <description>Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose PEF in First Week of Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured at 5 minutes after inhalation of study drug in the first week of treatment</time_frame>
    <description>Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-dose PEF in Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period (12 weeks)</time_frame>
    <description>Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Day in the Last Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in to the last week on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Day in the First Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in to the first week on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Day in the Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period (12 weeks)</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in COPD Symptoms - Breathing</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)</time_frame>
    <description>Change in breathing symptom score (from 0 (none) to 4 (severe)) from run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Symptoms - Cough</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)</time_frame>
    <description>Change in cough symptom score (from 0 (none) to 4 (almost constant)) from run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Symptoms Sputum</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)</time_frame>
    <description>Change in sputum symptom score (from 0 (none) to 4 (severe)) from run-in period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COPD Exacerbations</measure>
    <time_frame>Whole treatment period (12 weeks)</time_frame>
    <description>Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Night in the Last Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the last week on treatment</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Night in the First Week on Treatment</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment</time_frame>
    <description>change in the number of inhalations of reliever medication during day from run-in to the first week on treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Use of Reliever Medication During Night in the Whole Treatment Period</measure>
    <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the whole treatment period (12 weeks)</time_frame>
    <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">581</enrollment>
  <condition>Chronic Obstructive Pulmonary Disease (COPD)</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: Budesonide/formoterol (Symbicort Turbuhaler</intervention_name>
    <description>budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: ipratropium (AtroventTM)</intervention_name>
    <description>ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>theophylline SR</intervention_name>
    <description>theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated informed consent

          -  Men or women patients ≥ 40 years of age

          -  Diagnosis of COPD with symptoms for more than 2 years and there is a history of at
             least one COPD exacerbation requiring a course of oral steroids and/or antibiotics
             within 1-12 months before Visit 2

          -  Forced Expiratory Volume in 1 second (FEV1) ≤50% of predicted normal value,
             pre-bronchodilator and Forced Expiratory Volume in 1 second (FEV1) / Forced Vital
             Capacity (FVC) &lt; 70%, pre-bronchodilator

          -  Total symptom score of 2 or more per day for at least half of run-in period
             (breathing, cough and sputum scores from the diary card) and complete morning
             recordings of Digital Peak Flow Meter data at least 7 out of the last 10 days of the
             run-in period

        Exclusion Criteria:

          -  A history of asthma and seasonal allergic rhinitis before 40 years of age

          -  Patients who have experienced exacerbation of COPD requiring hospitalisation and /or
             emergency room treatment and/or a course of oral steroids and/or intravenous
             corticosteroids and/or antibiotics within 4 weeks prior to Visit 2 and/or during
             run-in period

          -  Patients with relevant cardiovascular disorder judged by the investigator

          -  Patients with glaucoma, prostatic hyperplasia or bladder-neck obstruction judged by
             the investigator

          -  Women who are pregnant, breast-feeding or of child-bearing potential judged by the
             investigator
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Samuel Chen</last_name>
    <role>Study Chair</role>
    <affiliation>AstraZeneca Singapore Pte Ltd</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Foshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhongshan</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Haikou</city>
        <state>Hainan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shijiazhuang</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tangshan</city>
        <state>Hebei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changsha</city>
        <state>Hunan</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shenyang</city>
        <state>Liaoning</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Qingdao</city>
        <state>Shandong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chengdu</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chongqin</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Da Lian</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ha'er Bing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huhehaote</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 8, 2011</study_first_submitted>
  <study_first_submitted_qc>August 11, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 12, 2011</study_first_posted>
  <results_first_submitted>November 25, 2013</results_first_submitted>
  <results_first_submitted_qc>August 11, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 26, 2014</results_first_posted>
  <last_update_submitted>August 11, 2014</last_update_submitted>
  <last_update_submitted_qc>August 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Severe chronic obstructive pulmonary disease (COPD) patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
    <mesh_term>Theophylline</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
          <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
        </group>
        <group group_id="P2">
          <title>Ipratropium + Theophylline SR</title>
          <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="292"/>
                <participants group_id="P2" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Patients Who Received Study Treatment</title>
              <participants_list>
                <participants group_id="P1" count="290"/>
                <participants group_id="P2" count="292"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Pts With Correct Randomized Treatment</title>
              <participants_list>
                <participants group_id="P1" count="290">Efficacy analysis used 290 patients. Safety analysis used 290+3=293 patients.</participants>
                <participants group_id="P2" count="289">Efficacy analysis used 292 patients. Safety analysis used 292-3=289 patients.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="276"/>
                <participants group_id="P2" count="261"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="31"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Condition under Investigation Worsened</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Two patients in 'Symbicort Turbuhaler + ipratropium + theophylline' group did not receive study treatment and were excluded from the analysis popolation. Thus the number of patients in that group is 290 (= 290 - 2).</population>
      <group_list>
        <group group_id="B1">
          <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
          <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
        </group>
        <group group_id="B2">
          <title>Ipratropium + Theophylline SR</title>
          <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="290"/>
            <count group_id="B2" value="292"/>
            <count group_id="B3" value="582"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63.8" spread="8.79"/>
                    <measurement group_id="B2" value="64.4" spread="8.76"/>
                    <measurement group_id="B3" value="64.1" spread="8.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="43"/>
                    <measurement group_id="B3" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="254"/>
                    <measurement group_id="B2" value="249"/>
                    <measurement group_id="B3" value="503"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pre-dose FEV1</title>
        <description>Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value</description>
        <time_frame>Baseline (week 0) and mean in treatment period (weeks 1, 6, 12) measured before inhalation of study drug</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose FEV1</title>
          <description>Ratio of pre-dose FEV1 (Forced Expiratory Volume in 1 second) in treatment period to baseline value</description>
          <population>FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.079" lower_limit="1.059" upper_limit="1.100"/>
                    <measurement group_id="O2" value="1.009" lower_limit="0.990" upper_limit="1.029"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>1.096</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FEV1 at 5 Minutes</title>
        <description>Ratio of post-dose FEV1 at 5 minutes to baseline value</description>
        <time_frame>Baseline (-2 weeks) and mean in treatment period (1, 6, 12 weeks) measured at 5 minutes after inhalation of study drug</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FEV1 at 5 Minutes</title>
          <description>Ratio of post-dose FEV1 at 5 minutes to baseline value</description>
          <population>FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.179" lower_limit="1.161" upper_limit="1.199"/>
                    <measurement group_id="O2" value="1.106" lower_limit="1.088" upper_limit="1.124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.067</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.044</ci_lower_limit>
            <ci_upper_limit>1.090</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FEV1 at 60 Minutes</title>
        <description>Ratio of post-dose FEV1 at 60 minutes to baseline value</description>
        <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FEV1 at 60 Minutes</title>
          <description>Ratio of post-dose FEV1 at 60 minutes to baseline value</description>
          <population>FAS</population>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.219" lower_limit="1.199" upper_limit="1.240"/>
                    <measurement group_id="O2" value="1.142" lower_limit="1.123" upper_limit="1.162"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.068</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>1.043</ci_lower_limit>
            <ci_upper_limit>1.092</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose FVC</title>
        <description>Ratio of pre-dose FVC (Forced Vital Capacity) to baseline</description>
        <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose FVC</title>
          <description>Ratio of pre-dose FVC (Forced Vital Capacity) to baseline</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
                <count group_id="O2" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.072" lower_limit="1.054" upper_limit="1.090"/>
                    <measurement group_id="O2" value="1.030" lower_limit="1.013" upper_limit="1.048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0007</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.040</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.017</ci_lower_limit>
            <ci_upper_limit>1.064</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FVC at 5 Minutes</title>
        <description>Ratio of post-dose FVC at 5 minutes to baseline</description>
        <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 5 minutes after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FVC at 5 Minutes</title>
          <description>Ratio of post-dose FVC at 5 minutes to baseline</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.170" lower_limit="1.153" upper_limit="1.188"/>
                    <measurement group_id="O2" value="1.120" lower_limit="1.104" upper_limit="1.137"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.045</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.024</ci_lower_limit>
            <ci_upper_limit>1.065</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose FVC at 60 Minutes</title>
        <description>Ratio of post-dose FVC at 60 minutes to baseline</description>
        <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose FVC at 60 Minutes</title>
          <description>Ratio of post-dose FVC at 60 minutes to baseline</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="288"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.192" lower_limit="1.174" upper_limit="1.211"/>
                    <measurement group_id="O2" value="1.148" lower_limit="1.130" upper_limit="1.166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0003</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.017</ci_lower_limit>
            <ci_upper_limit>1.060</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose IC</title>
        <description>Ratio of pre-dose IC (Inspiratory Capacity) to baseline</description>
        <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose IC</title>
          <description>Ratio of pre-dose IC (Inspiratory Capacity) to baseline</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="276"/>
                <count group_id="O2" value="264"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.068" lower_limit="1.045" upper_limit="1.092"/>
                    <measurement group_id="O2" value="1.032" lower_limit="1.010" upper_limit="1.056"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0248</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.004</ci_lower_limit>
            <ci_upper_limit>1.066</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose IC at 60 Minutes</title>
        <description>Ratio of post-dose IC at 60 minutes to baseline</description>
        <time_frame>Baseline (meaured before inhalation of study drug at week 0) and mean in treatment period (measured at 1 hour after inhalation of study drug at weeks 0, 1, 6, 12)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose IC at 60 Minutes</title>
          <description>Ratio of post-dose IC at 60 minutes to baseline</description>
          <units>Ratio</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="271"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.163" lower_limit="1.140" upper_limit="1.187"/>
                    <measurement group_id="O2" value="1.120" lower_limit="1.097" upper_limit="1.143"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0074</p_value>
            <method>ANCOVA</method>
            <method_desc>Multiplicative ANCOVA model with treatment and centre as fixed factors and baseline value as a (log-transformed) covariate</method_desc>
            <param_type>Ratio</param_type>
            <param_value>1.038</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.010</ci_lower_limit>
            <ci_upper_limit>1.067</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose PEF in Last Week of Treatment</title>
        <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in the last week of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose PEF in Last Week of Treatment</title>
          <description>Change in pre-dose morning PEF (Peak Expiratory Flow) from run-in period to last week of treatment</description>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="207"/>
                <count group_id="O2" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.135" lower_limit="13.808" upper_limit="32.462"/>
                    <measurement group_id="O2" value="-2.038" lower_limit="-11.678" upper_limit="7.603"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>25.172</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.733</ci_lower_limit>
            <ci_upper_limit>37.611</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose PEF in First Week of Treatment</title>
        <description>Change in pre-dose morning PEF from run-in period to first week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured before inhalation of study drug in the first week of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose PEF in First Week of Treatment</title>
          <description>Change in pre-dose morning PEF from run-in period to first week of treatment</description>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="228"/>
                <count group_id="O2" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.393" lower_limit="16.799" upper_limit="31.987"/>
                    <measurement group_id="O2" value="3.257" lower_limit="-4.357" upper_limit="10.871"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>21.136</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>12.163</ci_lower_limit>
            <ci_upper_limit>30.110</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-dose PEF in Whole Treatment Period</title>
        <description>Change in pre-dose morning PEF from run-in period to whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured before inhalation of study drug in whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Pre-dose PEF in Whole Treatment Period</title>
          <description>Change in pre-dose morning PEF from run-in period to whole treatment period</description>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="247"/>
                <count group_id="O2" value="246"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.021" lower_limit="14.563" upper_limit="27.479"/>
                    <measurement group_id="O2" value="-2.023" lower_limit="-8.555" upper_limit="4.510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>23.044</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.927</ci_lower_limit>
            <ci_upper_limit>31.161</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose PEF in Last Week of Treatment</title>
        <description>Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in the last week of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose PEF in Last Week of Treatment</title>
          <description>Change in post-dose morning PEF at 5 minutes from run-period to last week of treatment</description>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.612" lower_limit="26.656" upper_limit="46.569"/>
                    <measurement group_id="O2" value="5.100" lower_limit="-4.702" upper_limit="14.901"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>31.513</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.740</ci_lower_limit>
            <ci_upper_limit>44.286</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose PEF in First Week of Treatment</title>
        <description>Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurments measured at 5 minutes after inhalation of study drug in the first week of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose PEF in First Week of Treatment</title>
          <description>Change in post-dose morning PEF at 5 minutes from run-in period to first week of treatment</description>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="170"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25.993" lower_limit="17.330" upper_limit="34.656"/>
                    <measurement group_id="O2" value="1.670" lower_limit="-6.582" upper_limit="9.922"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>24.322</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>14.425</ci_lower_limit>
            <ci_upper_limit>34.220</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Post-dose PEF in Whole Treatment Period</title>
        <description>Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured at 5 minutes after inhalation of study drug in whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Post-dose PEF in Whole Treatment Period</title>
          <description>Change in post-dose morning PEF at 5 minutes from run-period to whole treatment period</description>
          <units>L/min</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="237"/>
                <count group_id="O2" value="239"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.507" lower_limit="19.892" upper_limit="33.122"/>
                    <measurement group_id="O2" value="-0.662" lower_limit="-7.278" upper_limit="5.955"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of pre-dose morning PEF as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>27.168</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>18.906</ci_lower_limit>
            <ci_upper_limit>35.431</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Day in the Last Week on Treatment</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in to the last week on treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the last week on treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Day in the Last Week on Treatment</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in to the last week on treatment</description>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="273"/>
                <count group_id="O2" value="266"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.398" lower_limit="-0.570" upper_limit="-0.226"/>
                    <measurement group_id="O2" value="-0.101" lower_limit="-0.276" upper_limit="0.074"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0102</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of reliever medication as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.297</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.522</ci_lower_limit>
            <ci_upper_limit>-0.071</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Day in the First Week on Treatment</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in to the first week on treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the first week on treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Day in the First Week on Treatment</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in to the first week on treatment</description>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.440" lower_limit="-0.583" upper_limit="-0.297"/>
                    <measurement group_id="O2" value="-0.097" lower_limit="-0.241" upper_limit="0.047"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0004</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of reliever medication as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.343</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.533</ci_lower_limit>
            <ci_upper_limit>-0.153</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Day in the Whole Treatment Period</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during day in the whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Day in the Whole Treatment Period</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="283"/>
                <count group_id="O2" value="285"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.404" lower_limit="-0.539" upper_limit="-0.268"/>
                    <measurement group_id="O2" value="-0.061" lower_limit="-0.197" upper_limit="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of reliever medication as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.342</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.523</ci_lower_limit>
            <ci_upper_limit>-0.162</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in COPD Symptoms - Breathing</title>
        <description>Change in breathing symptom score (from 0 (none) to 4 (severe)) from run-in period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Change in COPD Symptoms - Breathing</title>
          <description>Change in breathing symptom score (from 0 (none) to 4 (severe)) from run-in period</description>
          <units>Score from 0 to 4</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.507" lower_limit="-0.584" upper_limit="-0.431"/>
                    <measurement group_id="O2" value="-0.229" lower_limit="-0.305" upper_limit="-0.152"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of score as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.279</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.381</ci_lower_limit>
            <ci_upper_limit>-0.177</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Symptoms - Cough</title>
        <description>Change in cough symptom score (from 0 (none) to 4 (almost constant)) from run-in period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Symptoms - Cough</title>
          <description>Change in cough symptom score (from 0 (none) to 4 (almost constant)) from run-in period</description>
          <units>Score from 0 to 4</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.441" lower_limit="-0.516" upper_limit="-0.365"/>
                    <measurement group_id="O2" value="-0.248" lower_limit="-0.324" upper_limit="-0.172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of score as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.193</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.294</ci_lower_limit>
            <ci_upper_limit>-0.092</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Symptoms Sputum</title>
        <description>Change in sputum symptom score (from 0 (none) to 4 (severe)) from run-in period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements in the whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Symptoms Sputum</title>
          <description>Change in sputum symptom score (from 0 (none) to 4 (severe)) from run-in period</description>
          <units>Score from 0 to 4</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
                <count group_id="O2" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.332" lower_limit="-0.407" upper_limit="-0.257"/>
                    <measurement group_id="O2" value="-0.124" lower_limit="-0.200" upper_limit="-0.049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0001</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of score as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.208</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.308</ci_lower_limit>
            <ci_upper_limit>-0.108</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>COPD Exacerbations</title>
        <description>Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms</description>
        <time_frame>Whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>COPD Exacerbations</title>
          <description>Severe exacerbations requiring systemic steroids (oral ≥3 days or parenteral) or hospitalisation or emergency room treatment due to worsening of COPD symptoms</description>
          <units>exacerbations/12 weeks</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="290"/>
                <count group_id="O2" value="292"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.069" lower_limit="0.044" upper_limit="0.106"/>
                    <measurement group_id="O2" value="0.121" lower_limit="0.087" upper_limit="0.170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0425</p_value>
            <method>Poisson regression</method>
            <method_desc>Poisson regression model with treatment as a factor and the duration time in study as an offset variable</method_desc>
            <param_type>Rate ratio</param_type>
            <param_value>0.565</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.325</ci_lower_limit>
            <ci_upper_limit>0.981</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0880</p_value>
            <method>Regression, Cox</method>
            <method_desc>Time to the first COPD exacerbation</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.604</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.339</ci_lower_limit>
            <ci_upper_limit>1.078</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0845</p_value>
            <method>Log Rank</method>
            <method_desc>Time to the first COPD exacerbation</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Night in the Last Week on Treatment</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the last week on treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Night in the Last Week on Treatment</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="269"/>
                <count group_id="O2" value="263"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.078" lower_limit="-0.147" upper_limit="-0.009"/>
                    <measurement group_id="O2" value="-0.023" lower_limit="-0.093" upper_limit="0.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2281</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of reliever medication as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.055</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.144</ci_lower_limit>
            <ci_upper_limit>0.035</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Night in the First Week on Treatment</title>
        <description>change in the number of inhalations of reliever medication during day from run-in to the first week on treatment</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the first week on treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Night in the First Week on Treatment</title>
          <description>change in the number of inhalations of reliever medication during day from run-in to the first week on treatment</description>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="278"/>
                <count group_id="O2" value="282"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.124" lower_limit="-0.179" upper_limit="-0.068"/>
                    <measurement group_id="O2" value="-0.002" lower_limit="-0.057" upper_limit="0.053"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0010</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of reliever medication as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.122</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.194</ci_lower_limit>
            <ci_upper_limit>-0.049</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Use of Reliever Medication During Night in the Whole Treatment Period</title>
        <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
        <time_frame>Mean of daily measurements in run-in period (the last 10 days before randomization) and mean of daily measurements measured during night in the whole treatment period (12 weeks)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
            <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
          <group group_id="O2">
            <title>Ipratropium + Theophylline SR</title>
            <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
          </group>
        </group_list>
        <measure>
          <title>Use of Reliever Medication During Night in the Whole Treatment Period</title>
          <description>Change in the number of inhalations of reliever medication during day from run-in to the whole treatment period</description>
          <units>times/day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="280"/>
                <count group_id="O2" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.086" lower_limit="-0.144" upper_limit="-0.027"/>
                    <measurement group_id="O2" value="0.020" lower_limit="-0.038" upper_limit="0.079"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0073</p_value>
            <method>ANCOVA</method>
            <method_desc>Additive ANCOVA model with treatment and centre as fixed factors and the run-in mean of reliever medication as a covariate</method_desc>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.106</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.183</ci_lower_limit>
            <ci_upper_limit>-0.029</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Symbicort Turbuhaler + Ipratropium + Theophylline SR</title>
          <description>Symbicort Turbuhaler 160/4.5μg/inhalation, 2 inhalations twice daily) added to ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
        </group>
        <group group_id="E2">
          <title>Ipratropium + Theophylline SR</title>
          <description>ipratropium (AtroventTM 20 μg/inhalation, 2 inhalations four times daily) + theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="31" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Fungal oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Gastritis atrophic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Joint sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
              <event>
                <sub_title>Erythema of eyelid</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="293"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="289"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI shall not publish any results until the earlier of (i) the date of the first Study results publication authorized by AZ and (ii) the end of the 18 month period following the completion of the Study. PI shall provide AZ with such material for review, at least 60 days prior to submission for publication. If requested in writing by AZ, PI shall withhold material from submission for publication for an additional 90 days from the date of AZ's request.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Goran Eckerwall</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

